Re: Zenith trial partners

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

KOO-KOO2

Rank: Treasurer [?]

Points: 10765 [?]

Votes: 39 Score: 2.3 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith trial partners

in response to

Zenith trial partners

Payzone

posted on Jan 30, 2023 10:16AM

I see potentially multiple licencing of ZEN-3694 with multiple royalties for multiple indications in collaborations with multiple pharma.

And this needs Zenith to trade on the open market, not just on the OTC. The stock needs to be liquid for the shareholders to trade on the open market.

However, the first home run for ZEN-3694 in collaboration with a BP, management may decide to sell off the epigenetic drug. What they will do with the cash is another story.